scholarly journals Enolase 1 Regulates Stem Cell-Like Properties in Gastric Cancer Cells by Stimulating Glycolysis

2020 ◽  
Author(s):  
Ting Yang ◽  
Xiong Shu ◽  
Hui-Wen Zhang ◽  
Li-Xin Sun ◽  
Long Yu ◽  
...  

Abstract Background: Recent studies have demonstrated that gastric cancer stem cells (CSCs) are a rare sub-group of gastric cancer (GC) cells and play an important role in promoting the tumor growth and progression of GC. In the present study, we demonstrated that the glycolytic enzyme Enolase 1 (ENO1) was involved in the regulation of the stem cell-like characteristics of GC cells.Methods: Self-renewal, Chemosensitivity and invasion of GC cells were evaluated by sphere formation, Chemosensitivity assay and invasion assay respectively. Glycolysis level was examined by the Seahorse XFe/XF Analyzer. ENO1 expression was determined in 83 GC specimens by immunohistochemistry. Results: The expression of ENO1 in sphere cells markedly increased as compared to the parental cell lines PAMC-82 and SNU16. We then observed that ENO1 could enhance stem cell-like characteristics, including self-renewal capacity, cell invasion and migration, chemoresistance, and even the tumorigenicity of GC cells. ENO1 is known as an enzyme that is involved in glycolysis, and our results showed that ENO1 could markedly promote the glycolytic activity of cells. Furthermore, inhibiting glycolysis activity using 2-Deoxy-D-glucose treatment significantly reduced the stemness of GC cells. Therefore, ENO1 could improve the stemness of CSCs by enhancing the cells’ glycolysis. Subsequently, to further confirm our results, we found that the inhibition of ENO1 using AP-III-a4 (ENOblock) could reduce the stemness of GC cells to a similar extent as the knockdown of ENO1 by shRNA. Finally, increased expression of ENO1 was related with poor prognosis in GC patients. Conclusion: Taken together, our results demonstrated that ENO1 is a significant biomarker associated with the stemness of GC cells.

2020 ◽  
Vol 11 (10) ◽  
Author(s):  
Ting Yang ◽  
Xiong Shu ◽  
Hui-Wen Zhang ◽  
Li-Xin Sun ◽  
Long Yu ◽  
...  

Abstract Recent studies have demonstrated that gastric cancer stem cells (CSCs) are a rare sub-group of gastric cancer (GC) cells and have an important role in promoting the tumor growth and progression of GC. In the present study, we demonstrated that the glycolytic enzyme Enolase 1 (ENO1) was involved in the regulation of the stem cell-like characteristics of GC cells, as compared to the parental cell lines PAMC-82 and SNU16, the expression of ENO1 in spheroids markedly increased. We then observed that ENO1 could enhance stem cell-like characteristics, including self-renewal capacity, cell invasion and migration, chemoresistance, and even the tumorigenicity of GC cells. ENO1 is known as an enzyme that is involved in glycolysis, but our results showed that ENO1 could markedly promote the glycolytic activity of cells. Furthermore, inhibiting glycolysis activity using 2-deoxy-d-glucose treatment significantly reduced the stemness of GC cells. Therefore, ENO1 could improve the stemness of CSCs by enhancing the cells’ glycolysis. Subsequently, to further confirm our results, we found that the inhibition of ENO1 using AP-III-a4 (ENOblock) could reduce the stemness of GC cells to a similar extent as the knockdown of ENO1 by shRNA. Finally, increased expression of ENO1 was related to poor prognosis in GC patients. Taken together, our results demonstrated that ENO1 is a significant biomarker associated with the stemness of GC cells.


Author(s):  
Qiong Luo ◽  
Suyun Zhang ◽  
Donghuan Zhang ◽  
Rui Feng ◽  
Nan Li ◽  
...  

Background: Gastric cancer(GC) is currently one of the major malignancies that threatens human lives and health. Anlotinib is a novel small-molecule that inhibits angiogenesis to exert anti-tumor effects. However, the function in gastric cancer is incompletely understood. Objective: The aim of the present study was to investigate the anti-tumor effects and molecular mechanisms of anlotinib combined with dihydroartemisinin (DHA) in SGC7901 gastric cancer cells. Method: Different concentrations of anlotinib and DHA were used to treat SGC7901 gastric cancer cells, after which cell proliferation was measured. Drug interactions of anlotinib and DHA were analyzed by the Chou-Talalay method with CompuSyn software. proliferation, apoptosis, invasion, migration, and angiogenesis were measured using the cell counting kit-8 (CCK8) assay, flow cytometry, Transwell invasion assays, scratch assays, and chicken chorioallantoic membrane (CAM) assays. proliferation-associated protein (Ki67), apoptosis-related protein (Bcl-2), and vascular endothelial growth factor A (VEGF-A) were quantified by Western bloting. Results: The combination of 2.5 μmol/L of anlotinib and 5 of μmol/L DHA was highly synergistic in inhibiting cell growth, significantly increased the apoptosis rate and suppressed obviously the invasion and migration capability and angiogenesis of gastric cancer cells. In addition, the expression levels of Ki67, Bcl-2, and VEGF-A, as well as angiogenesis, were significantly decreased in the Combination of drugs compared with in control and either drug alone. Conclusion: The combination of anlotinib and DHA showed synergistic antitumor activity, suggesting their potential in treating patients with gastric cancer.


2020 ◽  
Vol Volume 13 ◽  
pp. 7985-7995
Author(s):  
Yuan Guo ◽  
Guochun Lu ◽  
Huahui Mao ◽  
Shengkun Zhou ◽  
Xiangmei Tong ◽  
...  

2018 ◽  
Vol Volume 11 ◽  
pp. 2753-2761 ◽  
Author(s):  
Dawei Rong ◽  
Chaoxi Dong ◽  
Kai Fu ◽  
Hanjin Wang ◽  
Weiwei Tang ◽  
...  

2013 ◽  
Vol 139 (6) ◽  
pp. 1033-1042 ◽  
Author(s):  
Hui Zhang ◽  
Lili Liu ◽  
Yafang Wang ◽  
Guohong Zhao ◽  
Rougang Xie ◽  
...  

2013 ◽  
Vol 34 (12) ◽  
pp. 2851-2860 ◽  
Author(s):  
Zhong-Yin Yang ◽  
He Jiang ◽  
Ying Qu ◽  
Min Wei ◽  
Min Yan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document